IL160271A0 - Pharmaceutical compositions containing pde4-inhibitors and nsaid - Google Patents

Pharmaceutical compositions containing pde4-inhibitors and nsaid

Info

Publication number
IL160271A0
IL160271A0 IL16027102A IL16027102A IL160271A0 IL 160271 A0 IL160271 A0 IL 160271A0 IL 16027102 A IL16027102 A IL 16027102A IL 16027102 A IL16027102 A IL 16027102A IL 160271 A0 IL160271 A0 IL 160271A0
Authority
IL
Israel
Prior art keywords
nsaid
inhibitors
pharmaceutical compositions
compositions containing
derivative
Prior art date
Application number
IL16027102A
Other languages
English (en)
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of IL160271A0 publication Critical patent/IL160271A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16027102A 2001-09-19 2002-09-17 Pharmaceutical compositions containing pde4-inhibitors and nsaid IL160271A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000473 2001-09-19
PCT/EP2002/010424 WO2003024489A2 (fr) 2001-09-19 2002-09-17 Combinaison d'un ains et d'un inhibiteur de pde4

Publications (1)

Publication Number Publication Date
IL160271A0 true IL160271A0 (en) 2004-07-25

Family

ID=8176065

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16027102A IL160271A0 (en) 2001-09-19 2002-09-17 Pharmaceutical compositions containing pde4-inhibitors and nsaid
IL160271A IL160271A (en) 2001-09-19 2004-02-08 Pharmaceutical compositions containing pde4-inhibitors and

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160271A IL160271A (en) 2001-09-19 2004-02-08 Pharmaceutical compositions containing pde4-inhibitors and

Country Status (25)

Country Link
US (2) US20040242597A1 (fr)
EP (1) EP1429807B1 (fr)
JP (1) JP4588998B2 (fr)
KR (1) KR100949528B1 (fr)
CN (1) CN100496607C (fr)
AT (1) ATE355080T1 (fr)
AU (1) AU2002337105B2 (fr)
BR (1) BR0212606A (fr)
CA (1) CA2459757C (fr)
CY (1) CY1108011T1 (fr)
DE (1) DE60218497T2 (fr)
DK (1) DK1429807T3 (fr)
EA (1) EA008108B1 (fr)
ES (1) ES2282469T3 (fr)
HK (1) HK1066730A1 (fr)
HU (1) HU229442B1 (fr)
IL (2) IL160271A0 (fr)
MX (1) MXPA04002562A (fr)
NO (1) NO331756B1 (fr)
NZ (1) NZ532278A (fr)
PL (1) PL210463B1 (fr)
PT (1) PT1429807E (fr)
SI (1) SI1429807T1 (fr)
WO (1) WO2003024489A2 (fr)
ZA (1) ZA200402654B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110424A1 (fr) * 2003-05-28 2004-12-23 Glaxo Group Limited Procede et formulation pharmaceutique pour reduire chez un mammifere l'acceleration du transfert colique induite par le stress
AU2004264722A1 (en) * 2003-08-07 2005-02-24 B.M.R.A. Corporation B.V. Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxigenase-1
CA2542277A1 (fr) * 2003-10-21 2005-05-12 Pharmacia Corporation Technique de traitement de prevention d'inflammation respiratoire avec un inhibiteur de cyclooxygenase-2 combine a un inhibiteur de phosphodiesterase 4 et compositions a partir deceux-ci
EP1683521A1 (fr) * 2005-01-21 2006-07-26 Centre National De La Recherche Scientifique (Cnrs) Inhibiteurs de la peptide deformylase, leur utilisations et compositions pharmacéutiques qui les contiennent
EP1688413A1 (fr) * 2005-02-03 2006-08-09 Hikma Pharmaceuticals Co. Ltd. Dérivés de benzoxazole pour la prophylaxie et le traitement des inflammations intestinales
WO2006097459A1 (fr) * 2005-03-14 2006-09-21 Nycomed Gmbh Procede de prevention des maladies cardiovasculaires
EP1898894A1 (fr) * 2005-06-17 2008-03-19 Boehringer Ingelheim International GmbH Inhibiteurs mrp iv pour le traitement de maladies respiratoires
ES2358763T3 (es) * 2006-04-28 2011-05-13 Grünenthal GmbH Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y un nsaid.
FR2909876A1 (fr) * 2006-12-19 2008-06-20 Galderma Res & Dev S N C Snc Utilisation du nepafenac ou ses derives pour le traitement de desordres dermatologiques
EA018462B1 (ru) 2008-01-25 2013-08-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК МОДУЛЯТОРЫ СИНТЕЗА TNF-α И КАК ИНГИБИТОРЫ PDE4
EP2265288B1 (fr) * 2008-03-04 2016-05-11 Labrys Biologics Inc. Procédés de traitement d'une douleur inflammatoire
WO2010097334A1 (fr) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Associations de médicaments contenant des inhibiteurs de pde4 et des ains
EP2400961B1 (fr) 2009-02-27 2017-11-22 Boehringer Ingelheim International GmbH Combinaisons de médicaments contenant des inhibiteurs pde4 et nsaid
MX2015010714A (es) 2013-02-19 2016-06-14 Pfizer Compuestos de azabencimidazol.
EP3172210B1 (fr) 2014-07-24 2020-01-15 Pfizer Inc Composés de pyrazolopyrimidine
KR102061952B1 (ko) 2014-08-06 2020-01-02 화이자 인코포레이티드 이미다조피리다진 화합물
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
EP4069213A1 (fr) * 2019-12-03 2022-10-12 The USA, as represented by The Secretary, Department of Health and Human Services Inhibition de la cyclooxygénase 2 permettant le traitement de l'asthme à saa élevé
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
US20230090417A1 (en) * 2021-09-22 2023-03-23 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
GB2228736A (en) 1989-02-10 1990-09-05 Sterivet Lab Ltd Cosmetic formulation
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
EA200000488A1 (ru) 1997-11-04 2000-10-30 Пфайзер Продактс Инк. Замена катехина на биоизостеру индазола в терапевтически активных соединениях
JP2003503360A (ja) 1999-06-24 2003-01-28 ファルマシア コーポレイション 炎症性疾患の処置のための併用療法
CA2715683A1 (fr) * 1999-08-21 2001-03-01 Nycomed Gmbh Combinaison synergiste
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
ECSP003747A (es) * 1999-11-02 2002-05-23 Smithkline Beecham Corp Metodo y composiciones para el tratamiento de las enfermedades pulmonares
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6372777B1 (en) * 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
CA2398182C (fr) * 2000-01-31 2007-03-13 Pfizer Products Inc. Derives benzocondenses heterocycliques de nicotinamide utiles comme inhibiteurs selectifs d'isozymes pde4
AU7205701A (en) * 2000-02-08 2001-08-20 Smithkline Beecham Corporation Method and compositions for treating an inflammatory disease
KR20030070150A (ko) * 2001-01-31 2003-08-27 화이자 프로덕츠 인크. Pde4 이소자임 억제제로서 유용한 에테르 유도체
CZ20032491A3 (cs) * 2001-02-15 2004-01-14 Altana Pharma Ag Ftalazinonpiperidinové deriváty

Also Published As

Publication number Publication date
DE60218497T2 (de) 2007-11-08
PL369472A1 (en) 2005-04-18
CA2459757C (fr) 2011-08-30
BR0212606A (pt) 2004-08-17
WO2003024489A3 (fr) 2003-09-18
HUP0401582A3 (en) 2008-04-28
NZ532278A (en) 2006-02-24
CN100496607C (zh) 2009-06-10
JP4588998B2 (ja) 2010-12-01
HU229442B1 (hu) 2013-12-30
US20040242597A1 (en) 2004-12-02
PT1429807E (pt) 2007-05-31
KR20040053129A (ko) 2004-06-23
ATE355080T1 (de) 2006-03-15
US8242146B2 (en) 2012-08-14
EA200400410A1 (ru) 2004-12-30
KR100949528B1 (ko) 2010-03-25
DE60218497D1 (de) 2007-04-12
EP1429807B1 (fr) 2007-02-28
MXPA04002562A (es) 2004-05-31
JP2005504077A (ja) 2005-02-10
CY1108011T1 (el) 2013-09-04
EA008108B1 (ru) 2007-04-27
WO2003024489A2 (fr) 2003-03-27
NO331756B1 (no) 2012-03-19
SI1429807T1 (sl) 2007-08-31
HUP0401582A2 (hu) 2004-11-29
PL210463B1 (pl) 2012-01-31
HK1066730A1 (en) 2005-04-01
CN1625411A (zh) 2005-06-08
ZA200402654B (en) 2005-04-26
US20080255209A1 (en) 2008-10-16
EP1429807A2 (fr) 2004-06-23
AU2002337105B2 (en) 2008-03-20
DK1429807T3 (da) 2007-06-18
NO20041596L (no) 2004-06-18
ES2282469T3 (es) 2007-10-16
IL160271A (en) 2008-03-20
CA2459757A1 (fr) 2003-03-27

Similar Documents

Publication Publication Date Title
IL160271A0 (en) Pharmaceutical compositions containing pde4-inhibitors and nsaid
BRPI0411825A (pt) inibidores de p38 quinase a base de heterociclo de 5 elementos
TW200511992A (en) Sulfonamide substituted imidazoquinolines
BR9914718A (pt) Formulações farmacêuticas de libertação controlada compreendendo um inibidor cgmp pde-5
EP1900362A3 (fr) Dérivés alpha-aminoamides utiles dans le traitement des troubles d'accoutumance
DK1198233T3 (da) Sulfonamid- og sulfamidsubstituerede imidazoquinoliner
NO20021424D0 (no) Granuler basert på stivelse og laktose
EE200100670A (et) Amiidasendatud imidasokinoliinid
MXPA04001088A (es) Derivados de pirazol como inhibidores de cinasa y uso de los mismos.
HK1056175A1 (en) Prodrugs of imidazopyridine derivatives
SE0102808D0 (sv) New compounds
MXPA04003910A (es) Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar.
AR045724A1 (es) Composicion farmaceutica orodispersable de un compuesto antitrombotico
YU83903A (sh) Farmaceutske kombinacije zasnovane na derivatima piridoindolona
EA200100876A3 (ru) Фармацевтическая композиция для предупреждения или лечения заболевания, связанного с избыточным продуцированием il-12
EA200602082A1 (ru) Производные индол-2-она для лечения расстройств центральной нервной системы, желудочно-кишечных расстройств и сердечно-сосудистых расстройств

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed